Neurology Clinical Trials Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Neurology Clinical Trials market is segmented by Phase (Phase I, Phase II, Phase III and Phase IV), Study Design (Interventional, Observational and Expanded Access), Indication (Epilepsy, Stroke, Alzheimer's Disease (AD), Parkinson's Disease (PD), and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Neurology Clinical Trials Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Neurology Clinical Trials Industry Overview

In the current scenario, the number of product launches, collaborations, and other strategies by the market players is increasing, and it's fueling the global neurology clinical trial market. The market is competitive in nature globally and fragmented due to the presence of several major players in the market. Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals), AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., Annovis Bio, Biogen, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Sanofi are some of the major players among others.

Neurology Clinical Trials Market Leaders

  1. AbbVie Inc.

  2. Biogen

  3. Merck & Co., Inc.

  4. Novartis AG

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
AbbVie Inc., Biogen, Merck & Co., Inc., Novartis AG, Sanofi

Global Neurology Clinical Trials Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?